Little Green Pharma (ASX:LGP) welcomed the French government's notification to the European Commission of the production and market authorization framework for medicinal cannabis, which establishes the pathway for full market legalization, according to a Wednesday Australian bourse filing.
It noted that the firm will continue to be one of the only two authorized companies supplying products at full price during the transition period to March 31, 2026, under the new framework.
All medicinal cannabis products will now require a common technical document submission for market authorization. The firm anticipates that the number of firms entering the French market will be limited, given the strict data requirements.
Its shares fell 4% on market close.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。